


Identifying another piece in the Parkinson's disease pathology puzzle

28 January 2016



Parkinson's researchers used proteomics to identify Rab proteins as a physiological substrate of LRRK2, a Parkinson's drug target. This finding may accelerate current research and open a novel therapeutic avenue. Credit: MPI of Biochemistry

An international public-private research consortium has identified and validated a cellular role of a primary Parkinson's disease drug target, the LRRK2 kinase. This important finding, published in the online, open-access *eLife* journal, illuminates a novel route for therapeutic development and intervention testing for Parkinson's, the second most common neurodegenerative disease after Alzheimer's.

A team of investigators from the Max Planck Institute of Biochemistry, the University of Dundee, The Michael J. Fox Foundation for Parkinson's Research (MJFF), GlaxoSmithKline (GSK) and MSD contributed unique tools and expertise toward rigorous systematic testing that determined the LRRK2 kinase regulates cellular trafficking by deactivating certain Rab proteins (3, 8, 10 and 12).

Mutations in the LRRK2 gene are the greatest

known genetic contributor to Parkinson's [disease](#). Pharmaceutical companies are developing LRRK2 kinase inhibitors to correct the effects of those mutations and treat Parkinson's disease. This new breakthrough finding that links mutant LRRK2 to inappropriate deactivation of Rab function unlocks more than 20 years of accumulated knowledge of the roles of Rab proteins. This knowledge can now be integrated to significantly improve our understanding of LRRK2 dysfunction in the Parkinson's disease process.

"The pathological cascade leading to brain diseases such as Parkinson's likely includes many cellular players," said Matthias Mann, PhD, Director of the Department of Proteomics and Signal Transduction at the Max Planck Institute of Biochemistry. "The identification of this LRRK2 substrate gives us a central piece in this puzzle and another potential place to intervene in the disease process."

Marco Baptista, PhD, MJFF Senior Associate Director of Research Programs, said, "Identification of Rab proteins as a LRRK2 substrate presents a tool to measure the impact of these inhibitors not only on LRRK2 levels but also on LRRK2 function. This critical component will advance development of these therapies to slow or stop Parkinson's disease, patients' greatest unmet need."

This MJFF-led consortium used a combination of tools in the discovery, including a knock-in mouse model of the most common LRRK2 mutation strongly associated with Parkinson's (created by GSK), a second knock-in LRRK2 mouse model generated by MJFF, LRRK2 kinase inhibitors from GSK and Merck, and state-of-the-art mass spectrometry. These tools—and the collaborative spirit that united the partners—were necessary to make this finding.

"This unique model of collaboration and our systematic approach across laboratories using

advanced technologies and layers of confirmation provide a firm foundation from which to continue this line of investigation and further refine our understanding of the LRRK2 Rab relationship," said Dario Alessi, PhD, Director of the Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee.

More information: Martin Steger et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases, *eLife* (2016). DOI: [10.7554/eLife.12813](https://doi.org/10.7554/eLife.12813)

Provided by Max Planck Society

APA citation: Identifying another piece in the Parkinson's disease pathology puzzle (2016, January 28) retrieved 22 September 2019 from <https://medicalxpress.com/news/2016-01-piece-parkinson-disease-pathology-puzzle.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.